Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.56 |
| ▸ | CA9 | Q16790 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | MAOB | P27338 | 7/20 | 0.53 |
| ▸ | MAOA | P21397 | 2/20 | 0.53 |
| ▸ | XDH | P47989 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | F12 | P00748 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27631823 | 0.95 | MAOB (0.55) | CA12CA9POLBMAOBMAOA | |
| SCHEMBL16943491 | 0.85 | CA12 (0.52) | CA12CA9POLBMAOBMAOA | |
| SCHEMBL2249264 | 0.85 | POLB (0.52) | CA12CA9POLBMAOBMAOA | |
| SCHEMBL29592689 | 0.85 | POLB (0.52) | CA12CA9POLBMAOBMAOA | |
| SCHEMBL3488219 | 0.84 | CA12 (0.68) | CA12CA9POLBMAOBMAOA | |
| SCHEMBL31290976 | 0.84 | CA12 (0.68) | CA12CA9POLBMAOBMAOA | |
| SCHEMBL12201092 | 0.83 | POLB (0.53) | CA12CA9POLBMAOBMAOA | |
| SCHEMBL23258715 | 0.83 | MEN1 (0.57) | CA12CA9POLBMAOBNPC1 | |
| SCHEMBL2102040 | 0.83 | NPC1 (0.56) | CA12CA9POLBMAOBMAOA | |
| SCHEMBL6239637 | 0.82 | POLB (0.58) | CA12CA9POLBMAOBMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 232 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11007193-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2021-05-18 | — | — | US | disclosed |
| US-11007193-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2021-05-18 | — | — | US | disclosed |
| US-10828301-B2 | 2,4-pyrimidinediamine compounds and their uses | Rigel Pharmceuticals, Inc. (US) | 2020-11-10 | — | — | US | disclosed |
| US-10709703-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2020-07-14 | — | — | US | disclosed |
| US-10682350-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2020-06-16 | — | — | US | disclosed |
| US-20200085820-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2020-03-19 | — | — | US | disclosed |
| US-20190255047-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2019-08-22 | — | — | US | disclosed |
| US-10369148-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2019-08-06 | — | — | US | disclosed |
| US-10314840-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2019-06-11 | — | — | US | disclosed |
| US-9913842-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2018-03-13 | — | — | US | disclosed |
| US-20030212070-A1 | Aminoalkyl-substituted aromatic bicyclic compounds, methods for their preparation and their use as pharmaceuticals | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-11-13 | — | — | US | disclosed |
| US-20030187053-A1 | Triamide-substituted heterobicyclic compounds | PFIZER INC. | 2003-10-02 | — | — | US | disclosed |
| WO-2003063794-A2 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2003-08-07 | — | — | WO | disclosed |
| US-6548530-B1 | Antitumor drugs incorporate the 1,2,9,9a-tetrahydrocyclopropa(c)benz(e)indol-4-one (CBI) alkylation subunit; cytotoxic activity | THE SCRIPPS RESEARCH INSTITUTE | 2003-04-15 | — | — | US | disclosed |
| WO-2003002533-A1 | TRIAMIDE-SUBSTITUTED INDOLES, BENZOFURANES AND BENZOTHIOPHENES AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN (MTP) AND/OR APOLIPOPROTEIN B (APO B) SECRETION | PFIZER PRODUCTS INC. (US) | 2003-01-09 | — | — | WO | disclosed |
| CN-1219841-A | DNA-binding indole derivatives, their prodrugs and immunoconjugates as anticancer agents | PANORAMA RES INC (US) | 1999-06-16 | — | — | CN | disclosed |
| EP-0862553-A4 | CBI ANALOGS OF CC-1065 AND THE DUOCARMYCINS | SCRIPPS RESEARCH INST (US) | 1999-02-03 | — | — | EP | disclosed |
| US-5843937-A | DNA-binding indole derivatives, their prodrugs and immunoconjugates as anticancer agents | PANORAMA RESEARCH, INC. (US) | 1998-12-01 | — | — | US | disclosed |
| EP-0862553-A1 | CBI ANALOGS OF CC-1065 AND THE DUOCARMYCINS | The Scripps Research Institute (US) | 1998-09-09 | — | — | EP | disclosed |
| WO-1997012862-A1 | CBI ANALOGS OF CC-1065 AND THE DUOCARMYCINS | THE SCRIPPS RESEARCH INSTITUTE (US) | 1997-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212070-A1 | Aminoalkyl-substituted aromatic bicyclic compounds, methods for their preparation and their use as pharmaceuticals | PER2, CNR2, DDC | CA12 4767/4885CA9 4364/4885POLB 1943/4885 |
| US-20200085820-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | FCER2, FCGR1A, FCGR2A | CA12 4754/4885CA9 4824/4885POLB 3063/4885 |
| US-10682350-B2 | 2,4-pyrimidinediamine compounds and their uses | FCER2, FCGR1A, FCGR2A | CA12 4754/4885CA9 4824/4885POLB 3063/4885 |
| US-20030187053-A1 | Triamide-substituted heterobicyclic compounds | APOB, LIPC, MTTP | CA12 4874/4885CA9 4752/4885POLB 1171/4885 |
| US-10709703-B2 | 2,4-pyrimidinediamine compounds and their uses | FCER2, FCGR1A, FCGR2A | CA12 4754/4885CA9 4824/4885POLB 3063/4885 |
| US-10314840-B2 | 2,4-pyrimidinediamine compounds and their uses | FCER2, FCGR1A, FCGR2A | CA12 4754/4885CA9 4824/4885POLB 3063/4885 |
| US-10369148-B2 | 2,4-pyrimidinediamine compounds and their uses | FCER2, FCGR1A, FCGR2A | CA12 4754/4885CA9 4824/4885POLB 3063/4885 |
| US-11007193-B2 | 2,4-pyrimidinediamine compounds and their uses | FCER2, FCGR1A, FCGR2A | CA12 4754/4885CA9 4824/4885POLB 3063/4885 |
| US-20190255047-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | FCER2, FCGR1A, FCGR2A | CA12 4754/4885CA9 4824/4885POLB 3063/4885 |
| US-10828301-B2 | 2,4-pyrimidinediamine compounds and their uses | FCER2, FCGR1A, FCGR2A | CA12 4754/4885CA9 4824/4885POLB 3063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.